Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 21, 2011

Icon and Acronet to Collaborate on Clinical Trial Management

  • Icon and Acronet will work together to offer clients a range of clinical development capabilities to manage trials on a regional or global basis. The Japanese firms say that the agreement was established because of the rising need from their clients in the country and outside for clinical trial management services.

    “Recent changes in the regulatory landscape mean that an increasing number of Japanese-based pharmaceutical companies are looking to run development projects on both a domestic and pan-regional basis,” says Alan Morgan, Icon’s group president, clinical research services.

    “The number of global clinical trials involving the triad regions of U.S., EU, and Japan has increased gradually in recent years and this trend will continue to accelerate,” notes Shogo Nakamori, Acronet’s president and CEO. “This is one of the challenging areas for the Japanese pharmaceutical industry, and Acronet is now ready to contribute and support the above challenging areas through this alliance with Icon.”

    With headquarters in Tokyo and additional offices in Osaka, Fukuoka, and New York, Acronet employs around 500 clinical development professionals. Icon has been operational in Japan since 1995 and offers a variety of clinical development services and contract staffing from its offices in Tokyo and Osaka.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »